FLCN and metabolic dysfunction-associated steatotic liver disease: To test whether protection against steatosis and NAFLD was due to cell-autonomous effects of Flcn KO in hepatocytes, we investigated whether loss of hepatic Flcn was also protective in a model of liver fibrosis that does not cause weight gain or insulin resistance.